Biotech Values

[xavierprivas]

May be the retail piled in due to the stupid Motley Fool

https://finance.yahoo.com/news/apos-why-omeros-corporation-stock-172900233.html

Quote near the end:
That said, the magnitude of the difference is hard to ignore. A majority of 19 patients treated with the experimental drug survived 347 days versus expectations of just 21 days based on past observations of patients with the lethal condition.

This is clearly misleading as the 100 days passed sometime near
the end of April 2018 and the CC clearly said they just had the
data compiled recently. There is a 53% survival rate vs 10% in
historical control at 100 days, but somehow the Motley Fool extrapolated to
347 days of survival which is in the future.